Advanced

The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions.

Kobelt, Gisela LU ; Texier-Richard, B and Lindgren, P (2009) In Multiple Sclerosis 15. p.741-751
Abstract
ObjectiveTo evaluate the long-term costs and quality of life (QoL) with and without disease-modifying treatments (DMTs) of patients with multiple sclerosis (MS).MethodsData on resource consumption, productivity losses, QoL (utility), and fatigue were collected from 1355 patients registered with a patient association and descriptive analyses was performed.A Markov model was developed to estimate costs and utility over 20 years using the survey data. Disease progression without DMTs was taken from an epidemiological cohort in France (EDMUS cohort, LYON). Progression under DMTs was estimated from the Stockholm MS registry. Results are presented as cost per quality-adjusted life-years (QALYs), from the societal perspective, in EUR2007,... (More)
ObjectiveTo evaluate the long-term costs and quality of life (QoL) with and without disease-modifying treatments (DMTs) of patients with multiple sclerosis (MS).MethodsData on resource consumption, productivity losses, QoL (utility), and fatigue were collected from 1355 patients registered with a patient association and descriptive analyses was performed.A Markov model was developed to estimate costs and utility over 20 years using the survey data. Disease progression without DMTs was taken from an epidemiological cohort in France (EDMUS cohort, LYON). Progression under DMTs was estimated from the Stockholm MS registry. Results are presented as cost per quality-adjusted life-years (QALYs), from the societal perspective, in EUR2007, discounted at 3%.ResultsMean Expanded Disability Status Scale (EDSS) was 4.4 and mean total annual costs per patient were EUR44,400, of which 47% were productivity losses and 11% informal care. Public payers cover an estimated 48% of costs. Mean utility was 0.52, and the loss compared with the normal population was estimated at 0.28. Costs and utility ranged from EUR16,000 and 0.79 at EDSS 1 to EUR76,000 and 0.11 at EDSS 8-9.Over 20 years, costs were estimated at EUR429,000 and QALYs at 8.96 for patients without DMTs and at EUR433,207 and 9.24 QALYs if all patients were starting treated with DMTs at EDSS 1-3.ConclusionAlthough the data for this analysis come from different sources, the results indicate that the cost increase with DMTs is moderate. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Multiple Sclerosis
volume
15
pages
741 - 751
publisher
Arnold, Hodder Headline PLC
external identifiers
  • wos:000267186000013
  • pmid:19383645
  • scopus:66149168700
ISSN
1477-0970
DOI
10.1177/1352458509102771
language
English
LU publication?
yes
id
3874ac16-49a7-4ce2-a79f-c4993fc4a372 (old id 1391951)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19383645?dopt=Abstract
date added to LUP
2009-05-05 15:32:44
date last changed
2017-04-23 04:33:01
@article{3874ac16-49a7-4ce2-a79f-c4993fc4a372,
  abstract     = {ObjectiveTo evaluate the long-term costs and quality of life (QoL) with and without disease-modifying treatments (DMTs) of patients with multiple sclerosis (MS).MethodsData on resource consumption, productivity losses, QoL (utility), and fatigue were collected from 1355 patients registered with a patient association and descriptive analyses was performed.A Markov model was developed to estimate costs and utility over 20 years using the survey data. Disease progression without DMTs was taken from an epidemiological cohort in France (EDMUS cohort, LYON). Progression under DMTs was estimated from the Stockholm MS registry. Results are presented as cost per quality-adjusted life-years (QALYs), from the societal perspective, in EUR2007, discounted at 3%.ResultsMean Expanded Disability Status Scale (EDSS) was 4.4 and mean total annual costs per patient were EUR44,400, of which 47% were productivity losses and 11% informal care. Public payers cover an estimated 48% of costs. Mean utility was 0.52, and the loss compared with the normal population was estimated at 0.28. Costs and utility ranged from EUR16,000 and 0.79 at EDSS 1 to EUR76,000 and 0.11 at EDSS 8-9.Over 20 years, costs were estimated at EUR429,000 and QALYs at 8.96 for patients without DMTs and at EUR433,207 and 9.24 QALYs if all patients were starting treated with DMTs at EDSS 1-3.ConclusionAlthough the data for this analysis come from different sources, the results indicate that the cost increase with DMTs is moderate.},
  author       = {Kobelt, Gisela and Texier-Richard, B and Lindgren, P},
  issn         = {1477-0970},
  language     = {eng},
  pages        = {741--751},
  publisher    = {Arnold, Hodder Headline PLC},
  series       = {Multiple Sclerosis},
  title        = {The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions.},
  url          = {http://dx.doi.org/10.1177/1352458509102771},
  volume       = {15},
  year         = {2009},
}